Brief: Spago Nanomedical: Tumorad Shows Good Safety In Preclinical Studies

Spago Nanomedical AB (publ)

06/12/2021 07:16

Dec 6 (Reuters) - Spago Nanomedical AB (publ)  SPAGO.ST :
    * TUMORAD SHOWS GOOD SAFETY IN PRECLINICAL STUDIES
    * HAS COMPLETED STUDIES IN REGULATORY PRECLINICAL PROGRAM
WITH ITS
LEADING CANDIDATE DRUG TUMORAD (SN201)
    * PLAN IS TO SUBMIT APPLICATION AND START STUDIES IN HUMANS
IN
2022

Source text for Eikon:  ID:nMFN7t89jk 
Further company coverage:  SPAGO.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;;))